References
Aapro, M., Abrahamsson, P. A., Body, J. J., Coleman, R. E., Colomer, R., Costa, L., … Thürlimann, B. (2008). Guidance on the use of bisphosphonates in solid tumors: Recommendations of an international expert panel. Annals of Oncology, 19, 420-432.
Barginear, M., Clotfelter, A., & Poznak, C. V. (2009). Markers of bone metabolism in women receiving aromatase inhibitors for early-stage breast cancer.
Clinical Breast Cancer, 9, 72-76.
http://dx.doi.org/10.3816/CBC.2009.n.014
Brufsky, A., Dong, M., Lund, K., Warsi, G., Cobb, P., Eisenberg, P., … Perez, E. (2006). Twenty-four month follow-up of the effect of zoledronic acid (ZA) on aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET) [Abstract 5060]. Breast Cancer Research and Treatment, 100(Suppl. 1), S233.
Bundred, N. J. (2009). Aromatase inhibitors and bone health. Current Opinion in Obstetrics and Gynecology, 21, 60-67.
Bundred, N. J., Campbell, I. D., Davidson, N., DeBoer, R. H., Eidtmann, H., Monnier, A., … Coleman, R. E. (2008). Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.
Cancer, 112, 1001-1010.
http://dx.doi.org/10.1002/cncr.23259
Burstein, H. J., Prestrud, A. A., Seidenfeld, J., Anderson H., Buchholz, T. A., Davidson, N. E., … Griggs, J. J. (2010). American Society of Clinical Oncology clinical practice guideline: Update on adjuvant and endocrine therapy for women with hormone receptor-positive breast cancer.
Journal of Clinical Oncology, 28, 3784-3796.
http://dx.doi.org/10.1200/JCO.2009.26.3756
Cazzaniga, M. E., Mustacchi, G., Pronzato, P., De Matteis, A., Di Costanzo, F., Floriani, I., … NORA Study Group. (2007). Adjuvant treatment of early breast cancer: Do the St. Gallen recommendations influence clinical practice? Results from the NORA study.
Annals of Oncology, 18, 1976-1980.
http://dx.doi.org/10.1093/annonc/mdm365
Clunie, G. P., Clark, A., Mortimer, C. J., Stephenson, S., Aitken, J., Smith, C., … Archer, T. J. (2009). Evaluating bone health in women with estrogen receptor positive breast cancer (ERBC) starting aromatase inhibitors. European
Journal of Surgical Oncology, 35, 475-480.
http://dx.doi.org/10.1016/j.ejso.2008.08.001
Delaney, M. F. (2006). Strategies for the prevention and treatment of osteoporosis during early postmenopause.
American Journal of Obstetrics and Gynecology, 194(Suppl. 2), S12-S23.
http://dx.doi.org/10.1016/j.ajog.2005.08.049
Gebara, S. N., & Moubayed, H. (2009). Risk of osteonecrosis of the jaw in cancer patients taking bisphosphonates. American Journal of Health System Pharmacy, 66, 1514-1517.
Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R. N., … Van Poznak, C. H. (2009). NCCN Task Force report: Bone health in cancer care. Journal of the National Comprehensive Cancer Network, 7(Suppl. 3), S1-S32.
Hadji, P., Body, J. J., Aapro, M. S., Brufsky, A., Coleman, R. E., Guise, T., … Tubiana-Hulin, M. (2008). Practical guidance for the management of aromatase inhibitor-associated bone loss.
Annals of Oncology, 19, 1407-1416.
http://dx.doi.org/10.1093/annonc/mdn164
Hadji, P., Ziller, M., Albert, U. S., & Kalder, M. (2010). Assessment of fracture risk in women with breast cancer using current VERSUS emerging guidelines.
British Journal of Cancer, 102, 645-650.
http://dx.doi.org/10.1038/sj.bjc.6605548
Hadji, P., Ziller, M., Kieback, D. G., Dornoff, W., Tessen, H. W., Menschik, T., … Hasenburg, A. (2009). Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: Results of a German, 12-month, prospective, randomised substudy.
Annals of Oncology, 20, 1203-1209.
http://dx.doi.org/10.1093/annonc/mdn762
Mouridsen, H., Giobbie-Hurder, A., Goldhirsch, A., Thürlimann, B., Paridaens, R., Smith, I., … Coates, A. S. (2009). Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.
New England Journal of Medicine, 361, 766-776.
http://dx.doi.org/10.1056/NEJMoa0810818
Perez, E. A. (2007). Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Annals of Oncology, 18(Suppl. 8), viii26-viii35.
Burstein, H. J., Prestrud, A. A., Seidenfeld, J., Anderson H., Buchholz, T. A., Davidson, N. E., … Griggs, J. J. (2010). American Society of Clinical Oncology clinical practice guideline: Update on adjuvant and endocrine therapy for women with hormone receptor-positive breast cancer. Journal of Clinical Oncology, 28, 3784-3796.
Clunie, G. P., Clark, A., Mortimer, C. J., Stephenson, S., Aitken, J., Smith, C., … Archer, T. J. (2009). Evaluating bone health in women with estrogen receptor positive breast cancer (ERBC) starting aromatase inhibitors.
European Journal of Surgical Oncology, 35, 475-480.
http://dx.doi.org/10.1016/j.ejso.2008.08.001
Hadji, P., Body, J. J., Aapro, M. S., Brufsky, A., Coleman, R. E., Guise, T., … Tubiana-Hulin, M. (2008). Practical guidance for the management of aromatase inhibitor-associated bone loss. Annals of Oncology, 19, 1407-1416.
Hadji, P., Ziller, M., Kieback, D. G., Dornoff, W., Tessen, H. W., Menschik, T., … Hasenburg, A. (2009). Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: Results of a German, 12-month, prospective, randomised substudy. Annals of Oncology, 20, 1203-1209.
Mortimer, J. E. (2010). Managing the toxicities of the aromatase inhibitors. Current Opinion in Obstetrics and Gynecology, 22, 56-60.
Perez, E. A. (2007). Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Annals of Oncology, 18(Suppl. 8), viii26-viii35.
Thorne, C. (2007). Clinical management of arthralgia and bone health in women undergoing adjuvant aromatase inhibitor therapy. Current Opinion in Oncology, 19(Suppl. 1), S19-S28.